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ABSTRACT: Oxidation/reduction of thiol residues in proteins is an important type of post-translational modification that 
is implicated in regulating a range of biological processes. The nature of the modification makes it possible to define a 
quantifiable electrochemical potential, 𝐸𝐸⊕, for oxidation/reduction that allows cysteine-containing proteins to be ranked 
based on their propensity to be oxidized. Measuring oxidation of cysteine residues in proteins is difficult using standard 
electrochemical methods but recently top-down mass-spectrometry has been shown to enable the quantification of 𝐸𝐸⊕for 
thiol oxidations. In this paper we demonstrate that mass spectrometry of intact proteins can be used in combination with 
an isotopic labeling strategy and an automated data analysis algorithm to measure 𝐸𝐸⊕for the thiols in both E Coli Thiore-
doxin 1 and Human Thioredoxin 1. Our methodology relies on accurate mass measurement of proteins using LC-MS anal-
yses and does not necessarily require top-down fragmentation. As well as analyzing homogeneous protein samples, we 
also demonstrate that our methodology can be used to determine thiol 𝐸𝐸⊕ measurements in samples which contain mix-
tures of proteins. Thus the combination of experiential methodology and data analysis regime have the potential to make 
such measurements in a high-throughput manner and in a manner more accessible to a broad community of protein sci-
entists. 
Over the past three decades oxidative thiol modifica-
tion has emerged as a central mechanism for dynamic 
post-translational regulation of protein activity and pro-
tein signaling pathways. In 1992, Stamler et al. investigat-
ed the S-nitrosylation of protein cysteine thiols as a re-
versible covalent modification important in vasodilation.1 
In 2000, Finkel published a review article in which he 
suggested ‘the covalent addition of glutathione to reactive 
cysteines may be one mechanism for achieving reversible 
redox-dependent signaling as well as a potential means 
for identifying relevant redox-dependent signaling mole-
cules.2 Since then, it has become apparent that many im-
portant biological pathways are subject to redox regula-
tion through such oxidation-reduction reactions.3-5 For 
example, in the intrinsic apoptotic pathway, the apoptosis 
regulator protein Bax has been shown to undergo oxida-
tive activation through disulfide formation; and activation 
of the initiator caspase Casp9 has been shown to occur via 
intermolecular disulfide formation with apoptotic prote-
ase activating factor 1 (APAF1).6,7 Interestingly, redox reg-
ulation seems to be particularly prevalent amongst tran-
scription factors (TF), where cysteine modifications can 
control function via several mechanisms. For example, in 
the AP-1 family of TFs, Cys oxidation has been shown to 
induce conformational change, inhibiting DNA-binding.8 
In contrast, Nuclear factor-like 2 (NRF2) activity is con-
trolled by oxidation of its partner protein KEAP1; disulfide 
formation in KEAP1 results in a reduced affinity for NRF2, 
allowing translocation of NRF2 into the nucleus and 
transactivation of target genes.9 In a recent study of the 
tumor suppressor TF p53, we demonstrated that oxidation 
of cysteines within the binding site of the essential zinc 
ion, results in metal loss, a reduction in protein stability 
and impaired DNA-binding.10As well as modulating pro-
tein-protein interactions, there are also many examples of 
redox regulation of enzyme activity. Of particular note, 
examples of both kinases and phosphatases have been 
shown to be regulated by redox chemistry – highlighting 
how the cellular oxidative environment can potentially 
influence the phosphoproteome. A clear example of this is 
found in the members of the PI3K–AKT–mTOR signaling 
pathway, which is important for regulation of the cell 
cycle. The kinase Akt2 is inhibited by oxidation, either 
through the formation of a disulfide bond or the oxida-
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tion of a thiol to a sulfenic acid – both of these modifica-
tions are chemically reversible under biological condi-
tions.11 In addition, the activity of the tumour suppressor 
phosphatase PTEN, which is the main regulator of the 
PI3K–AKT–mTOR pathway, can be controlled by both 
disulfide formation or oxidative modification of its active 
site cysteine residue.11 
As a consequence of the central importance of this 
emerging regulatory mechanism, there is a growing need 
for chemical and analytical tools for the identification and 
characterization of redox sensitive cysteines. Here we 
outline a mass spectrometry based method for the charac-
terisation and quantification of Cys redox modification 
based on their biochemical standard potential (𝐸𝐸⨁) and 
demonstrate the utility of the procedure using the 
well-characterized protein thioredoxin. The protein thi-
oredoxin is ubiquitous across the kingdoms and acts as a 
reductant for a number of proteins, in a variety of biologi-
cal pathways and it is thought to play an important role in 
the regulation of apoptosis.11,12 Its active site contains a 
CXXC motif with the cysteine residues responsible for its 
redox activity. As well as the catalytically active residues, 
human thioredoxin 1 (hTRX1) contains an additional three 
cysteine residues (Cys61, Cys68 & Cys72). The role of 
these non-active site residues is less well known; however, 
Watson et al. have determined that Cys61 and Cys68 are 
capable of forming a disulfide bond.13 
In biological systems, the propensity for a thiol to un-
dergo oxidative post-translational modification can be 
quantified in terms of its biochemical standard redox po-
tential 𝐸𝐸⨁. 𝐸𝐸⨁ is defined under standard biochemical 
conditions where all reactants are at unit activity except 
H+ which has a concentration of 10-7 M (i.e. pH = 7). The 
relationship between 𝐸𝐸⨁, the relative concentrations of 
reduced and oxidized proteoforms and the environmental 
potential (𝐸𝐸) is described by the Nernst Equation. For 
example for a protein with two cysteines that can form an 
intramolecular disulfide the standard potential can be 
defined as the potential at which there are equal concen-
trations of the disulfide and dithiol forms: 
 
𝐸𝐸 = 𝐸𝐸⊕ + 𝑅𝑅𝑅𝑅
𝑛𝑛𝑛𝑛
𝑙𝑙𝑙𝑙
[𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷][𝐷𝐷𝐷𝐷𝐷𝐷ℎ𝐷𝐷𝑖𝑖𝐷𝐷]    Equation 1 
 
From Equation 1 two things are clear: 
• If 𝐸𝐸 can be controlled and the ratio of the oxi-
dized and reduced proteoforms measured, 𝐸𝐸⨁ 
can be experimentally determined. 
• knowing 𝐸𝐸⨁for a protein is important because 
it allows one to predict the most thermody-
namically stable proteoform in a particular 
biological environment. 
Typically, measuring 𝐸𝐸⨁ for a protein is not trivial. 
Electrochemical techniques such as cyclic voltammetry 
are well suited to metal-centred redox reactions, but tend 
not to work particularly well for protein thiols as the ki-
netics of electron transfer are slower.  
A variant of Western Blotting has been employed to 
measure protein 𝐸𝐸⨁ and an advantage of the redox blot-
ting technique is the ability to probe the redox state of a 
specific protein from a complex mixture such as cell ly-
sate.13 However, the technique assumes that an antibody 
binds with equal affinity to differently alkylated and dif-
ferently oxidized proteoforms which may not be true for 
all antibodies.  
Recently, we highlighted the potential of using mass 
spectrometry as an analytical technique for the character-
ization of redox proteins.3 MS has the ability to determine 
the chemical nature of redox modifications based on ac-
curate protein mass measurements. For example, disul-
fide bond formation is accompanied by the loss of two 
hydrogen ions (a mass decrease of 2 Da) and glutathi-
onylation involves the addition of GSH to a specific Cys 
side chain via a disulfide bond (a mass increase of 305 
Da). Furthermore, protease digestion and/or tandem MS 
experiments can be employed to locate the site of specific 
redox modifications within a protein. Finally, we outlined 
a differential isotope labeling strategy which could allow 
the accurate quantification of the ratio of the oxidized 
and reduced proteoforms of a redox active protein, thus 
allowing the determination of 𝐸𝐸⨁for a specific cysteine 
oxidation event.  
This methodology was subsequently adapted by 
Scotcher et al., who used a differential isotope labeling 
strategy together with top-down mass spectrometry to 
determine 𝐸𝐸⨁for thioredoxin.14  
The inclusion of top-down fragmentation in the work-
flow has two notable advantages. Firstly, it provides mul-
tiple isotopologue product ions pairs, all of which can be 
used for quantification of the relative ratios of oxidized 
and reduced proteoforms, thus this methodology provides 
multiple replicates in a single top-down spectrum. Sec-
ondly, fragmentation of the intact protein prior to mass 
analysis has the potential to delineate multiple redox ac-
tive sites within a single protein. However, despite these 
advantages, the use of top-down fragmentation in the 
workflow limits the experimental throughput. Top-down 
fragmentation requires skilled user input and compara-
tively long data acquisition times. Thus the top-down 
process is not well suited for automated workflows or 
hyphenation to liquid chromatography separation.  
In principle, for proteins with single redox active sites, 
the ratio of oxidized and reduced proteoforms can be ac-
curately determined based solely on the ratio of light and 
heavy isotopologue in the intact protein mass spectrum. 
Here, we show that this is indeed the case and demon-
strate the utility of a differential isotope labeling strategy 
coupled with intact mass analysis by characterizing the 
redox potential of cysteines in human thioredoxin. Analy-
sis of overlapping isotope distributions in mass spectra of 
isotope labeled intact proteins is a greater challenge than 
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with protein fragments and we developed a bespoke soft-
ware package (NEMESIS) that greatly simplifies and au-
tomates this process. In principle, this workflow is appli-
cable to a range of LC-ESI-MS instrumentation and works 
with mixtures of proteins. The use of LC-MS for data ac-
quisition and tailored software for data analysis allows the 
process to be automated; thus opening the door for high-
er throughput analysis of protein redox modifications.  
 
MATERIALS & METHODS 
Materials 
Escherichia coli thioredoxin 1 (E. coli TRX1) was bought 
from Sigma Aldrich, resuspended in distilled water at 100 
μM, aliquoted and stored at -20 ˚C. All solvents were LC-
MS grade unless stated otherwise. 
Expression of recombinant wild type and active 
site mutant human TRX1 in E. coli. 
BL21(DE3) competent cells (Agilent Technologies) were 
transformed with pET16a plasmids containing the hTRX1 
gene or the active site mutant hTRX1 (C31,34S) with N-
terminal 6His tags provided by the Blom group.15 500 ml 
cultures of 2YT media were used for protein expression. 
Cells were grown to an optical density of 0.6 at A600nm at 
37 ⁰C before induction with 1 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG). Cells were harvested after 3 
hours. After freezing at -20 °C, the cell pellet was resus-
pended in chromatography buffer A (20 mM Tris pH 7.4, 
0.5 M NaCl, 20 mM imidazole) and sonicated for 15 
minutes (30 seconds on, 30 seconds off) to achieve lysis. 
After removal of the cellular debris, the supernatant was 
filtered before loading onto a 1ml HisTrap HP column (GE 
Healthcare). 
An AKTA purification system (GE Healthcare) operated 
by Unicorn was used for affinity chromatography. After 
protein loading, the column was washed to baseline be-
fore an elution gradient from 0 – 100% buffer B (20 mM 
Tris pH 7.4, 0.5 M NaCl, 1 M imidazole) over 40 column 
volumes was performed. Protein containing fractions 
were pooled and loaded onto a HiLoad Superdex 75 
(16/60) for size exclusion chromatography and eluted over 
1.5 column volumes with 50 mM Tris-HCl, pH 7.0, 150 mM 
NaCl. Again, protein containing fractions were pooled 
and concentrated with 5 KDa molecular weight cut off 
spin filters. The protein was stored at -20 °C. 
Redox Titration 
Redox buffered solutions consisting of either DL-
dithiothreitol (DTTRED) and 4,5-dihydroxy-1,2-dithiane 
(DTTOX) in 50 mM Tris pH 7.0 or glutathione (GSH) and 
glutathione disulfide (GSSG) in 100 mM sodium phos-
phate pH 7.0 were set up as detailed in Tables S1-S4. The 
Nernst equation was used to calculate the solution poten-
tial (considering an 𝐸𝐸⨁ of -0.330 V vs NHE for the DTT 
redox pair).16 The protein (10 μM) was equilibrated for 120 
minutes at 25 °C before the reduced cysteine residues 
were alkylated with 5 mM of the first alkylation reagent - 
eitherN-ethyl-d5-maleimide (dNEM) or N-ethylmaleimide 
(NEM). Alkylation was allowed to proceed for 30 minutes. 
The alkylation reaction was quenched by precipitating the 
protein with the addition of an equal volume of ice cold 
20% (w/v) trichloroacetic acid (TCA). The resulting pre-
cipitate was resuspended and reduced with 8 mM TCEP. 
After reduction was complete, alkylation of the remaining 
cysteine residues was achieved by addition of 10 mM of 
the second alkylation reagent (NEM or dNEM) and incu-
bation for 30 minutes.  
Each redox condition was performed in triplicate and 
the mean of the three experimental replicates was used to 
fit the sigmoidal curve. The standard deviation of the ex-
perimental replicates was used as the error for each spe-
cific potential and the errors quoted for 𝐸𝐸⨁ are the errors 
associated with the fit of the sigmoidal function. For the 
avoidance of doubt, all potentials reported in this paper 
are measured relative to the normal hydrogen electrode 
(NHE).  
It is important to note that this labeling strategy is in-
dependent of the order of NEM and dNEM labeling. In 
initial experiments we showed that the use of light or 
heavy NEM could be interchanged in the procedure with-
out influencing the final result (data not shown). 
LC-MS Analysis 
High performance liquid chromatography was per-
formed on a Dionex Ultima 3000 (Thermo Scientific) us-
ing a reverse phase monolithic PS-DVB (500 μm × 50 mm) 
analytical column. Buffer A consisted of H2O & 0.03 % 
trifluroacetic acid, and Buffer B consisted of 100 % ace-
tonitrile & 0.03 % trifluoroacetic acid. The column was 
operated at 60 °C with a flow rate of 15 μl/min. Typically, 
5 μl injections of 5 uM protein were performed. After pro-
tein loading, the column was washed for 5 minutes at 0 % 
buffer B and 5 minutes at 20 % buffer B before a linear 
elution gradient from 20 – 100 % buffer B was applied over 
15 minutes. The instrument was operated using Chro-
meleon and for the on-line coupling of LC to MS, the 
Bruker Daltonics software ‘HyStar’ was used. 
Mass spectrometry was performed on a SolariX FT-ICR 
mass spectrometer equipped with a 12 Tesla supercon-
ducting magnet (Bruker Daltonics). The instrument was 
operated in the positive ion mode with a capillary voltage 
of 4 kV. The drying gas was set to 180⁰C and 4L/min. The 
nebuliser gas pressure was 5 bar. Typically ions were ac-
cumulated for 200ms-1000ms and data was collected at 
1MWord.  
Data Analysis 
LC-MS data was analyzed in DataAnalysis software 
(Bruker Daltonics) and deconvoluted mass spectra were 
obtained using the maximum entropy (MaxEnt) algo-
rithm. These spectra were then analysed using in house 




 Figure 1: The differential cysteine labeling strategy and typical MS analysis using E. coli TRX1 equilibrated at -280 mV as an ex-
ample. A) An outline of the differential labeling workflow. B) The typical charge state distribution for E. coli TRX1, the insert 
shows the isotope distribution of the 11+ charge state and highlights the two labelled proteoforms of E. coli TRX1. C) The maxi-
mum entropy deconvoluted mass of the alkylated protein.  
RESULTS & DISCUSSION 
Differential Alkylation strategy and Quantification 
of alkylated proteoforms. 
To test our approach to measuring 𝐸𝐸⨁for protein thiols 
we chose E. coli Thioredoxin (E. coli TRX1) since it is a 
well characterized simple protein with only two thiols 
(Cys32 and Cys35) that are known to form a single intra-
molecular disulfide bond (see table S5 for protein se-
quence). By incubating the protein in a DTT buffer of 
potential -280 mV vs NHE and using the isotopic labeling 
protocol we can see two distinct populations by intact 
protein mass spectrometry. LC-MS reveals two similar 
charge state distributions separated by a mass difference 
of 10 Da (Fig 1) which corresponds to the difference in 
mass between thioredoxin labeled with 2 NEM and thi-
oredoxin labeled with 2 dNEM. This observation confirms 
that, at this specific redox potential, E. coli TRX1 exists as 
two distinct proteoforms in solution and that they can be 
discriminated using isotopic labeling and intact protein 
MS. In common with all isotope labeling MS strategies, 
we assume that the ESI ionization potential of these two 
species after alkylation is identical and thus ratiometric 
determination of the MS signal abundance of the two 
species allows their relative ratio to be accurately deter-
mined.  
Data Analysis 
It is clear for Fig 1B and 1C that the isotope distributions 
for the two proteoforms of thioredoxin overlap in the 
mass spectrum. Due to the widening of isotope distribu-
tions as molecular weight increases, this phenomenon 
will become more pronounced in larger intact protein 
systems. In order to determine the ratio of proteoforms at 
a given potential we need to separate the overlapping 
populations of alkylated proteins. To facilitate this in an 
automated manner suitable for high-throughput analysis 
we developed “NEM Evolutionary System for Isotopic 
Solutions” (NEMESIS) which is bespoke software, devel-
oped in LabVIEW (National Instruments, Austin, Tx, 
USA). NEMESIS uses a genetic algorithm to produce an 
approximately pareto-optimal solution to the relative in-
tensities of the overlapping isotopic distributions record-
ed in a given spectrum. The genetic algorithm has been 
described previously17 and was adapted for use by the de-
velopment of a new fitness function for this task.  
The workflow for NEMESIS starts with loading the de-
convoluted mass spectrum in profile form, for the region 
containing the overlapping isotopic distributions of inter-
est. A simple peak detection algorithm is use to identify 
the position and normalized intensity of the peaks in this 
region.18 The assumption is made that the spectrum is of a 
resolving power such that the peaks in the distributions 
are sufficiently resolved so that the peak centroid posi-
tions are not limited by resolving power, but not suffi-
ciently resolved such that the isotopologue peaks of the 
same nominal mass from adjacent distributions can be 
distinguished by the small mass differences between 
them. This means that the intensities of overlapping 
isotopologue peaks from adjacent distributions are taken 
to sum to give the intensity seen in the mass spectrum for 
that mass. It is also assumed that the spectrum is not 
heavily contaminated with other ions. 
The protein sequence is entered using single letter ab-
breviations and NEMESIS identifies the number of cyste-
ine residues present. NEMESIS uses the Mercury algo-
rithm developed by Rockwell, Orden and Smith,19,20 to 
calculate the normalized isotopic distribution of the ions 
produced from this sequence with every possible combi-
nation of NEM and dNEM for that protein, assuming that 
there is one addition of either NEM or dNEM at each cys-
teine. So, for a system with three cysteines, there would 
be four possible labelled combinations, where L denotes 
NEM and H denotes dNEM: [3L,0H], [2L1H], [1L2H] and 
[0L3H]. Or, more generally, for a protein with n cys resi-
dues there will be n+1 possible combinations of light and 
heavy labelled cys numbering from 0 (all light NEM) to n 
(all heavy dNEM). The mass of the peaks in each distribu-
tion are rounded to nominal masses so that they can be 
easily aligned with the spectral masses.  The isotopic dis-
tributions should be generated such that the modelled, 
synthetic spectra produced match the spectral resolution 




Figure 2: Key steps in the NEMESIS algorithm. A) A synthetic mass spectrum showing the normalized modelled isotop-
ic distributions of the five possible combinations resulting from differential labeling of the four cysteine residues in an 
example protein comprising 100 Tyr and 4 Cys. B) The effect of scaling the distributions from (A) by the relative propor-
tions 0.5, 0.01, 0.2, 0.3 and 0.1. C) The normalized total synthetic spectrum resulting from summing the distributions in 
(B). 
 
The complete distribution of peaks in the recorded 
mass spectrum comes from the sum of the intensities of 
ions from all combinations at each nominal mass. 
NEMESIS attempts to find the relative proportions of 
each combination that, when all the peak intensities are 
summed appropriately, would give the closest possible 
approximation of the recorded mass spectrum. An exam-
ple of this process is shown in Figure 2 for an example 
protein comprising Tyr100Cys4, where (A) shows the initial 
modelled (i.e. synthetic) distribution for the 5 possible 
combinations; (B) shows the combinations scaled to pro-
portions of 0.5, 0.01, 0.2, 0.3 and 0.1 for [4L, 0H], [3L, 1H], 
[2L, 2H], [1L, 3H] and [0L, 4H] respectively; and (C) shows 
the total distribution that would result from summing the 
separate distributions from (B). 
A modelled version of the complete peak distribution 
can be simply defined by the relative proportions of each 
of the combinations described above, as shown in Figure 
2 (C). We can define this total distribution using a simple 
ordered list just by recording the relative proportion (I) 
for each combination: [I0, I1, … In]. Each different possible 
distribution can be defined in this way, and in the termi-
nology of genetic algorithms, this is the genetic represen-
tation of each solution. So, the genetic representation of 
the distribution shown in Figure 2 (C) would be [0.5, 0.01, 
0.2, 0.3, 0.1]. 
NEMESIS then tests a series of generations of possible 
solutions (defined by their genetic representations) to the 
recorded mass spectrum – the first generation is created 
randomly (n=50) where each In in each member is a ran-
domly generated fraction between 0 and 1.  In all subse-
quent generations of solutions, the members of the new 
population are generated from the fittest solutions from 
the previous generation as described previously. The fit-
ness of each member in the population of solutions, in 
every generation, is estimated simply by the normalized 
root mean square error between the recorded spectral 
peak intensities and the sum of the modelled distribu-
tions in each case for each nominal mass. Only those 
masses that correspond to peaks in the modelled, syn-
thetic spectra are considered – not all masses across the 
complete mass range of the recorded mass spectrum. The 
fittest members of every generation are preferentially 
used to generate the next generation in a conventional 
genetic algorithm approach, using exhaustive cross-over 
and low probability random mutation (probability p=0.25, 
mutation range, r=1). The fittest member of each genera-
tion is compared to the fittest member of the previous 
generationand once the fitness ceases to increase by more 
than 0.05% from generation to generation, the system is 
deemed optimized and the genetic representation of fit-
test member of the final generation is output as the solu-
tion. 
One benefit of genetic algorithm optimization is that the 
technique is robust to changes in initial parameters.  For 
example, changing any (or indeed all) of the parameters 
of the genetic algorithm used in NEMESIS by an order of 
magnitude makes no statistical difference to the final re-
sult although it may take more generations to reach the 
solution. 
Redox Titrations and the Determination of 𝐄𝐄⨁ by 
Intact Protein Mass Measurement – E. coli Thiore-
doxin.  
 We then performed the differential labeling protocol 
on E. coli TRX1 incubated in the DTT redox couple at nine 
defined reduction potentials ranging from -309 to -257 
mV. After intact mass analysis, only two protein popula-
tions are observed at all potentials tested. The masses of 
these populations are consistent with intact E. coli TRX1 
with the two cysteines alkylated with either two dNEM or 
two NEM labels. It is clear that a smooth transition occurs 
between the two proteoforms as redox potential increas-
es. Furthermore, the observation that both cysteines in 
the protein transition from the oxidised to reduced state 
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at the same potential demonstrates that the two residues 
share the same mid-point potential, indicative of the for-
mation of a disulfide bond between the two residues. This 
is in agreement with the literature and the catalytic 
mechanism of the protein. 
 
 
Figure 3: Determination of 𝐸𝐸⨁ in E. coli TRX1. A) A waterfall 
plot showing the deconvoluted mass spectrum of E.coli TRX1 
at different reduction potential and after differential NEM 
labeling. Note: dNEM was used in the first alkylation step. B) 
A plot of the percentage of the oxidised proteoform against 
the redox potential of the initial equilibration buffer (relative 
to the standard hydrogen electrode). A sigmoidal trendline 
was fitted to the data, error bars show 1 standard deviation 
for n=3.  
The ratio of oxidised to reduced E. coli TRX1 was then 
calculated by using NEMESIS to determine the ratio of 
the two dNEM to two NEM labelled species. By plotting 
the percentage of the oxidised proteoform of the protein 
against the redox potential of the DTT solution, it is pos-
sible to determine 𝐸𝐸⨁from a sigmoidal trendline (in this 
case the point on the trendline at which there are equal 
amounts of reduced and oxidised proteoforms). From the 
trendline fitted in 3B, the mid-point potential of the two 
cysteine residues in E. coli TRX1 was found to be -281.5 ± 
0.2 mV. This is in good agreement with both established 
and recent literature publications which have established 
this potential to lie between -270 mV and -284 mV.14  
The method described here involves a number of ad-
vantages over established techniques used to investigate 
redox proteins, most notably: the low cost and availability 
of the reagents, the small sample volumes required, and 
the automation of data processing. 
Human Thioredoxin 
In contrast to E. coli TRX, the human form of Thiore-
doxin 1 (hTRX1) has five cysteine residues (Table S5). 
hTRX1 contains the characteristic N-terminal CGPC motif 
(with Cys31 and Cys34) as well as three further C-terminal 
Cys residues (Cys61, Cys68 and Cys72)   Therefore this 
protein constitutes a more challenging target for analysis 
using our methodology. By equilibrating hTRX1 in the 
same DTT buffer system as we used for E. coli TRX1 and 
employing the same dual labeling protocol, we see that 
there are two proteoforms present over this range of po-
tentials – corresponding to the fully reduced hTRX1 and 
hTRX1 containing two thiols that oxidise at the same po-
tential (characteristic of disulfide formation). By plotting 
the ratio of oxidised to reduced proteoforms over this 
range we can calculate an 𝐸𝐸⨁ for this process of -276 ± 1 
mV (Fig 4).  
 
Figure 4: Determination of 𝐸𝐸⨁ of Cys31 & Cys 34 in hTRX1 by 
plotting the percentage of the oxidised proteoform as deter-
mined using the differential alkylation protocol against the 
initial equilibration potential. The sigmoidal trendline fitted 
indicates that the residues have an 𝐸𝐸⨁ of -276 ± 1 mV. The 
error bars show one standard deviation from the mean for n 
= 3 experimental replicates. 
 
Figure 5: Determination of 𝐸𝐸⨁ for hTRX1 and hTRX1 (C31,34S). A) A waterfall plot showing the deconvoluted mass spectrum of 
hTRX between -309 and -269mV reduction potential and after differential NEM labeling. Note: dNEM was used in the first alkyl-
ation step. B) A plot of the percentage of the oxidised proteoform (2NEM3dNEM) against the redox potential of the initial equi-
libration buffer. A sigmoidal trendline was fitted to the data, which indicates that the residues have an 𝐸𝐸⨁ of -283± 3 mV; error 
bars show 1 standard deviation for n=3.C) A waterfall plot showing the deconvoluted mass spectrum of hTRX C31,34S mutant 
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between -309 and -269mV reduction potential and after differential NEM labeling, which shows no significant oxidation under 
these conditions.   
 
Figure 6: NEMESIS was used to quantify the labeling state of hTRX1 after equilibration in glutathione redox buffers and applica-
tion of the differential alkylation protocol. (A) A waterfall plot showing the deconvoluted mass spectrum of hTRX1 between -240 
and -80 mV and after differential NEM labeling. (B) Determination of the 𝐸𝐸⨁of Glutathionylation of Cys72. The percentage of 
the oxidised proteoform hTRX1 with a glutathionylation (labelled as hTRX1+2NEM+3dNEM), relative to the reduced proteoform 
(hTRX1 with only the active site residues oxidised, hTRX1+3NEM+2dNEM) The sigmoidal line of best fit indicates an 𝐸𝐸⨁of -204.4 
± 1.4 mV. (C) Determination of 𝐸𝐸⨁ of the disulfide bond between Cys61 and Cys68. The sigmoidal line of best fit indicates 𝐸𝐸⨁of -
162.4 ±_1.3 mV. (error bars show 1 standard deviation; for n=3 experimental replicates). 
This observation is consistent with a recent literature 
report by Scotcher et al.  which demonstrates that the 
thioredoxin active site cysteines (Cys31 and Cys34) form 
an intermolecular disulfide bond at -281 mV.14  .By em-
ploying top-down fragmentation we can clearly confirm 
that the two cysteines which form this disulfide bond are 
indeed Cys31 and Cys34 (see supporting information Fig 
S1).  
As an alternative approach to confirm that the disulfide 
forms between the active site cysteine residues, we car-
ried out the same experiment using both the wild type 
protein (hTRX1) and an active site cysteine to serine mu-
tant hTRX1(C31,34S). The two proteins were mixed and 
incubated in a series of redox buffers together before MS 
analysis and data analysis (Fig 5). Although the two spe-
cies co-elute on the LC column, the mass difference be-
tween the two proteins allowed them to be distinguished 
in the mass spectrometer. Under these experimental con-
ditions we determined the 𝐸𝐸⨁ of disulfide bond formation 
in wild-type hTRX1 to be -283± 3 mV (Fig 5A and 5B). It is 
interesting to note that the presence of a mixture of pro-
teins in the sample had little effect on the 𝐸𝐸⨁ determine 
for wild-type hTRX1.  Figure 5C shows that over the po-
tential range measured, there is no significant oxidation 
of the 3 C-terminal cysteines in the hTRX1(C31,34S) mu-
tant and confirms that the process observed in Figure 5A 
is disulfide formation between the two active site cyste-
ines. 
These data demonstrate that the intact mass of differ-
entially labelled proteins can be used to determine 𝐸𝐸⨁for 
specific cysteine residues. Furthermore we demonstrate 
the relative ease of adapting our protocol for the determi-
nation of 𝐸𝐸⨁of multiple proteins in the same experiment. 
Thus highlighting the potential for its future use to inves-
tigate electron transfer reactions between proteins. 
Since the three C-terminal cysteines (Cys61, Cys68, 
Cys72) are predominantly reduced under the potentials 
determined by DTT solutions, we used mixtures of gluta-
thione and glutathione disulfide to investigate their redox 
regulation. This redox couple allows us to set more oxidis-
ing reduction potentials. At these more oxidising condi-
tions it was clear that two further redox transitions took 
place in the C-terminal region of hTRX1. These were iden-
tified by top down fragmentation as Glutathionylation of 
Cys72 and intramolecular disulfide bond formation be-
tween Cys61 and Cys68 (see supporting information Fig 
S2).  
Figure 6 shows the deconvoluted mass spectrum for 
hTRX1 over the potential range -239 mV to -89 mV. Note 
that for this set of experiments the differential labelling 
strategy was reversed. The first labeling step, which alkyl-
ated the initially reduced cysteines, was performed with 
NEM; the second labeling step was performed using 
dNEM.  
By using NEMESIS to quantify the differentially labeled 
protein populations and plotting these against potential 
we can quantify 𝐸𝐸⨁ for both the glutationylation and the 
disulfide formation (Fig 6B and 6C). The 𝐸𝐸⨁for the gluta-
thionylation is -204.4 mV and that for the disulfide for-
mation is -162.4 mV. 
 
CONCLUSION 
We have demonstrated the utility of intact protein 
mass-spectrometry in the determination of the redox 
characteristics of a biologically important protein. The 
technique that we have developed relies jointly on a dif-
ferential isotope labeling strategy and bespoke software 
based on a genetic algorithm to determine the ratio of 
oxidized to reduced proteoforms at potentials applied 
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using soluble redox couples. By plotting the degree of 
oxidation against potential we can determine 𝐸𝐸⨁for the 
protein. We have demonstrated that this protocol can be 
used to measure 𝐸𝐸⨁ of proteins in mixtures and to deter-
mine 𝐸𝐸⨁ for multiple redox processes within the same 
protein. For simple systemBy avoiding fragmentation we 
have made the process of determining 𝐸𝐸⨁ for a protein 
faster and compatible with an LC-MS timescale thus ena-
bling automated, high-throughput analysis. An additional 
advantage of our workflow is the capability to measure 
multiple protein redox potentials in the same experiment. 
The NEMESIS software also greatly simplifies the process 
of determining 𝐸𝐸⨁, thus making this type of analysis ac-
cessible to a greater range of non-specialist users. 
NEMESIS is available to academic users on request. 
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